Search

Your search keyword '"Giuseppe, L"' showing total 155 results

Search Constraints

Start Over You searched for: Author "Giuseppe, L" Remove constraint Author: "Giuseppe, L" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
155 results on '"Giuseppe, L"'

Search Results

3. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

5. 18F-FDG

8. Nature-Based Treatment Systems for Reclaimed Water Use in Agriculture in Mediterranean Countries

9. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

10. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

11. Cogging Torque Suppression of Modular Permanent Magnet Machines Using a Semi-Analytical Approach and Artificial Intelligence

12. 55 years of devoted service to medicine, morphology and pedagogy (on the 80th anniversary of the birth of Professor N.R. Karelina)

13. Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

14. Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

15. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

17. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study

18. Enhancing Conversion Efficiency of Direct Ink Write Printed Copper (I) Sulfide Thermoelectrics via Sulfur Infusion Process

19. Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

20. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

23. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

24. Effects of Solids Accumulation on Greenhouse Gas Emissions, Substrate, Plant Growth and Performance of a Mediterranean Horizontal Flow Treatment Wetland

27. External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations

29. Ultrasound and computed tomography diagnostics of ovarian cyst rupture with hemoperitoneum

30. Prevalence and features of delirium in older patients admitted to rehabilitation facilities

32. Prevalence and features of delirium in older patients admitted to rehabilitation facilities: a multicenter study

33. Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 <scp>OAK</scp> trial

34. Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

37. Data from Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

38. Supplemental Table 1 from Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

39. Supplemental Methods from Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

40. Supplemental Figures 1-14 from Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

41. Could hydraulic parameters variation affect the vegetation development in treatment wetlands?

43. Supplemental Methods from Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

44. Supplemental Figures 1-14 from Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

45. Data from Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

46. Supplemental Table 1 from Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

49. One-year nutrition counselling in the context of a Mediterranean diet reduced the dietary inflammatory index in women with breast cancer: a role for the dietary glycemic index

50. A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score

Catalog

Books, media, physical & digital resources